Business development


As part of the global Synthon organization, Synthon Biopharmaceuticals is well-positioned to build on the success, infrastructure and organization of the - financially independent, privately held and profitable - parent company.

In terms of partnering its (pre)clinical stage programs, Synthon Biopharmaceuticals is in a position to choose the optimum commercial path for each program: to develop a product to the market or, alternatively, to partner a technology or product candidate at the appropriate stage or value inflection point.

Antibody-drug conjugates
Synthon develops next generation ADC products, both independently and in collaboration/partnerships with biopharmaceutical companies that have suitable cancer antibody programs. We will consider in-licensing antibodies as well as co-developing ADCs with companies that have high quality antibodies, in order to build a balanced portfolio of ADC candidates. We are also interested to out-license our linker-drug technology to leading antibody companies.

Synthon Biopharmaceuticals welcomes to review business opportunities that are generally complementary to our portfolio and fit in our strategy. For collaborative or (in/out) licensing opportunities, co-development partnerships or other partnering opportunities, please contact us at: